

Formulary Update

September 2021

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since July 2021. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale
-----------	------------	--

Additions	Indication	Adult Medicines Formulary entry/ rationale
-----------	------------	--

Changes in preferred brand	New preferred brand	Adult Medicines Formulary entry
----------------------------	---------------------	---------------------------------

Buprenorphine 7-day patch	Sevodyne®	4.7.2 MCEG project
Calcium/ vitamin D preparations	1 st line: Adcal D3® One A Day chewable tablets.	9.6.4 MCEG project
Estradiol vaginal tablets	Vagirux®	7.2.1 MCEG project
Lipegfilgrastim	Pelgraz®	9.1.6 MCEG project

Other changes	Changes made	Adult Medicines Formulary entry/ rationale
---------------	--------------	--

Emollient preparations	New preferred choices agreed for creams, ointments, gels, lotions, bath & shower emollients	13.2 Formulary section review
Diabetes medicines	Clarification that prescribers experienced in diabetes care in both primary care and acute setting can initiate most diabetic medication. Highlighting which medicines require consultant initiation.	6.1 Follow-up from formulary section review

Contact us [here](#)